On April 24, 2024 HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, reported that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting May 31-June 4, 2024, in Chicago, IL (Press release, HighField Biopharmaceuticals, APR 24, 2024, View Source [SID1234642319]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The ASCO (Free ASCO Whitepaper) meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators," said Yuhong Xu, Ph.D., Founder and CEO of HighField. "Our lipid-based structures represent a new generation of therapeutics targeting the tumor microenvironment for a broad range of cancers."
The abstracts reflect Phase 1 clinical trials of two kinds of lipid-based therapeutics. HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression. HER2 expressing solid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.
HFK1 Poster Presentation
Abstract ID: 3035
Title: The design, preclinical study and Phase 1 dose escalation of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
Presenter: Dr. Yuhong Xu, Ph.D.
Presenter Date: Saturday, June 1, 2024 (9am -12pm)
HF1K16 Abstract for Publication
Abstract ID.: e14030
Title: Exploratory phase 1 study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: preliminary efficacy and mechanism as a monotherapy.